Teniposide

• CAT Number: A000506
• CAS Number: 29767-20-2
• Molecular Formula: C32H32O13S
• Molecular Weight: 656.7
• Purity: ≥95%
• Synonyms: Vumon; VM-26; 29767-20-2; Vehem; Teniposidum
• Target: Topoisomerase
• Solubility: >23.7mg/mL in DMSO
• Storage: -20°C
• InChIKey: NRUKOCRGYNPUPR-QBPJDGROSA-N

Teniposide is a semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle.

Reference

1: Yan J, Sun J, Zeng Z. Teniposide ameliorates bone cancer nociception in rats
via the P2X7 receptor. Inflammopharmacology. 2017 Aug 20. doi:
10.1007/s10787-017-0388-2. [Epub ahead of print] PubMed PMID: 28825192.

2: Chu B, Shi S, Li X, Hu L, Shi L, Zhang H, Xu Q, Ye L, Lin G, Zhang N, Zhang X.
Preparation and evaluation of teniposide-loaded polymeric micelles for breast
cancer therapy. Int J Pharm. 2016 Nov 20;513(1-2):118-129. doi:
10.1016/j.ijpharm.2016.09.005. Epub 2016 Sep 3. PubMed PMID: 27596115.

3: Zhang Y, Liu G, Lang M, Zhang J, Geng J. Patients treatment with neuroglioma
by teniposide and semustine and its influence on Twist and E-cadherin expression.
Saudi Pharm J. 2016 May;24(3):299-304. doi: 10.1016/j.jsps.2016.04.001. Epub 2016
May 5. PubMed PMID: 27275118; PubMed Central PMCID: PMC4880946.

4: Liu H, Liao JX, Hu Y, Tu YH, Sun JS. A Highly Efficient Approach To Construct
(epi)-Podophyllotoxin-4-O-glycosidic Linkages as well as Its Application in
Concise Syntheses of Etoposide and Teniposide. Org Lett. 2016 Mar
18;18(6):1294-7. doi: 10.1021/acs.orglett.6b00216. Epub 2016 Feb 26. PubMed PMID:
26916150.

5: He S, Cui Z, Wang X, Zhang H, Dai W, Zhang Q. Cremophor-free intravenous
self-microemulsions for teniposide: Safety, antitumor activity in vitro and in
vivo. Int J Pharm. 2015 Nov 10;495(1):144-53. doi: 10.1016/j.ijpharm.2015.08.005.
Epub 2015 Aug 4. PubMed PMID: 26253377.

6: He X, Xiang N, Zhang J, Zhou J, Fu Y, Gong T, Zhang Z. Encapsulation of
teniposide into albumin nanoparticles with greatly lowered toxicity and enhanced
antitumor activity. Int J Pharm. 2015 Jun 20;487(1-2):250-9. doi:
10.1016/j.ijpharm.2015.04.047. Epub 2015 Apr 18. PubMed PMID: 25899285.

7: He S, Yang H, Zhang R, Li Y, Duan L. Preparation and in vitro-in vivo
evaluation of teniposide nanosuspensions. Int J Pharm. 2015 Jan 15;478(1):131-7.
doi: 10.1016/j.ijpharm.2014.11.020. Epub 2014 Nov 13. PubMed PMID: 25448575.

8: Nguyen TT, Jung SJ, Kang HK, Kim YM, Moon YH, Kim M, Kim D. Production of
rubusoside from stevioside by using a thermostable lactase from Thermus
thermophilus and solubility enhancement of liquiritin and teniposide. Enzyme
Microb Technol. 2014 Oct;64-65:38-43. doi: 10.1016/j.enzmictec.2014.07.001. Epub
2014 Jul 11. PubMed PMID: 25152415.

9: Sun YC, Wang J, Guo CC, Sai K, Wang J, Chen FR, Yang QY, Chen YS, Wang J, To
TS, Zhang ZP, Mu YG, Chen ZP. MiR-181b sensitizes glioma cells to teniposide by
targeting MDM2. BMC Cancer. 2014 Aug 25;14:611. doi: 10.1186/1471-2407-14-611.
PubMed PMID: 25151861; PubMed Central PMCID: PMC4155117.

10: Wu JJ, Wang XH, Li L, Li X, Zhang L, Sun ZC, Fu XR, Ma W, Chang Y, Zhang XD,
Han LJ, Zhang MZ. Fotemustine, teniposide and dexamethasone in treating patients
with CNS lymphoma. Asian Pac J Cancer Prev. 2014;15(11):4733-8. PubMed PMID:
24969912.